Vaccine safety - is the SARS-CoV-2 vaccine any different?
Vaccines have changed modern medicine, and are a mainstay in reducing morbidity and mortality from infections. Our research group recently published a study in which we found that vaccines approved by the US Food and Drugs Administration were safe with few clinically important post-approval adverse...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Taylor & Francis Group,
2021-05-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_c993ac3c1f8545efb7c12a54f7afd9c6 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Noam Tau |e author |
| 700 | 1 | 0 | |a Dafna Yahav |e author |
| 700 | 1 | 0 | |a Daniel Shepshelovich |e author |
| 245 | 0 | 0 | |a Vaccine safety - is the SARS-CoV-2 vaccine any different? |
| 260 | |b Taylor & Francis Group, |c 2021-05-01T00:00:00Z. | ||
| 500 | |a 2164-5515 | ||
| 500 | |a 2164-554X | ||
| 500 | |a 10.1080/21645515.2020.1829414 | ||
| 520 | |a Vaccines have changed modern medicine, and are a mainstay in reducing morbidity and mortality from infections. Our research group recently published a study in which we found that vaccines approved by the US Food and Drugs Administration were safe with few clinically important post-approval adverse effects. The current COVID-19 pandemic presents regulators with the unprecedented challenge of balancing a public demand for the rapid development and approval of a safe and effective SARS-CoV-2 vaccine without compromising the strict pre-marketing requirements used for previous vaccines. Here, we review the approval process and safety profiles of FDA approved vaccines and discuss some of the challenges currently facing the FDA regarding the SARS-CoV-2 vaccine approval. | ||
| 546 | |a EN | ||
| 690 | |a vaccine | ||
| 690 | |a vaers | ||
| 690 | |a fda | ||
| 690 | |a safety | ||
| 690 | |a covid-19 | ||
| 690 | |a sars-cov-2 | ||
| 690 | |a Immunologic diseases. Allergy | ||
| 690 | |a RC581-607 | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Human Vaccines & Immunotherapeutics, Vol 17, Iss 5, Pp 1322-1325 (2021) | |
| 787 | 0 | |n http://dx.doi.org/10.1080/21645515.2020.1829414 | |
| 787 | 0 | |n https://doaj.org/toc/2164-5515 | |
| 787 | 0 | |n https://doaj.org/toc/2164-554X | |
| 856 | 4 | 1 | |u https://doaj.org/article/c993ac3c1f8545efb7c12a54f7afd9c6 |z Connect to this object online. |